Evidence map›Paper›PMID 26884167›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function.

Samuel E Marsh, Edsel M Abud, Anita Lakatos, Alborz Karimzadeh, Stephen T Yeung, Hayk Davtyan, Gianna M Fote, Lydia Lau, Jason G Weinger, Thomas E Lane and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 256 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
256citing papers in PubMed, 2 pooled it
22.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

256 citing papers in PubMed, 2 syntheses or guidelines pooled it, 411 citations in OpenAlex.

  1. Meta-Analysis of Transcriptomic Studies of Blood and Six Brain Regions Identifies a Consensus of 15 Cross-Tissue Mechanisms in Alzheimer's Disease and Suggests an Origin of Cross-Study Heterogeneity.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Engineering chimeric antigen receptor CD4 T cells for Alzheimer's disease.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  20. Article

196 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Samuel E MarshDepartment of Neurobiology and Behavior, University of California, Irvine, CA 92697; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697;ORCID http://orcid.org/0000-0002-3012-6945
Edsel M AbudDepartment of Neurobiology and Behavior, University of California, Irvine, CA 92697; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697;
Anita LakatosInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697;
Alborz KarimzadehSue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697;
Stephen T YeungInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697;
Hayk DavtyanDepartment of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647.
Gianna M FoteDepartment of Neurobiology and Behavior, University of California, Irvine, CA 92697; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697;
Lydia LauInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697;
Jason G WeingerDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697;
Thomas E LaneSue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697;
Matthew A InlaySue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697;
Wayne W PoonInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697;
Mathew Blurton-JonesDepartment of Neurobiology and Behavior, University of California, Irvine, CA 92697; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697; mblurton@uci.edu.
University of California, Irvine · USInstitute for Molecular Medicine · US

Funding

UC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI LAFERLA, FRANK M · 2000 to 2019
$37.0M
TISSUE REPOSITORY COREP01AG000538 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI LAFERLA, FRANK M · 1985 to 2018
$24.8M
Training in the Neurobiology of Aging and Alzheimers DiseaseT32AG000096 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI VIVEK SWARUP, Craig E Stark · 1985 to 2026
$9.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008620 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI GOLDIN, ALAN L · 1999 to 2023
$8.1M
Training Program in Stem Cell Translational Medicine for Neurological DisordersT32NS082174 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI PETER John DONOVAN, Leslie Michels Thompson · 2013 to 2026
$3.3M
The role of TREM2 in human microglial function and Alzheimer disease pathogenesisRF1AG048099 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI BLURTON-JONES, MATHEW MARK · 2014 to 2014
$1.9M
NIA NIH HHS P01 AG000538NIA NIH HHS P50 AG016573NIA NIH HHS RF1 AG048099NIA NIH HHS RF1AG048099NIA NIH HHS T32 AG000096NIA NIH HHS T32 AG00096-30NIGMS NIH HHS T32 GM008620NINDS NIH HHS T32 NS082174
6 · The paper itself

Abstract

The innate immune system is strongly implicated in the pathogenesis of Alzheimer's disease (AD). In contrast, the role of adaptive immunity in AD remains largely unknown. However, numerous clinical trials are testing vaccination strategies for AD, suggesting that T and B cells play a pivotal role in this disease. To test the hypothesis that adaptive immunity influences AD pathogenesis, we generated an immune-deficient AD mouse model that lacks T, B, and natural killer (NK) cells. The resulting "Rag-5xfAD" mice exhibit a greater than twofold increase in β-amyloid (Aβ) pathology. Gene expression analysis of the brain implicates altered innate and adaptive immune pathways, including changes in cytokine/chemokine signaling and decreased Ig-mediated processes. Neuroinflammation is also greatly exacerbated in Rag-5xfAD mice as indicated by a shift in microglial phenotype, increased cytokine production, and reduced phagocytic capacity. In contrast, immune-intact 5xfAD mice exhibit elevated levels of nonamyloid reactive IgGs in association with microglia, and treatment of Rag-5xfAD mice or microglial cells with preimmune IgG enhances Aβ clearance. Last, we performed bone marrow transplantation studies in Rag-5xfAD mice, revealing that replacement of these missing adaptive immune populations can dramatically reduce AD pathology. Taken together, these data strongly suggest that adaptive immune cell populations play an important role in restraining AD pathology. In contrast, depletion of B cells and their appropriate activation by T cells leads to a loss of adaptive-innate immunity cross talk and accelerated disease progression.

Indexed as

Adaptation, PhysiologicalAlzheimer DiseaseAmyloid beta-PeptidesAnimalsHumansImmunoglobulin GMiceMicrogliaPhagocytosisAmyloid beta-PeptidesImmunoglobulin GAlzheimer’samyloidIgGinflammationmicroglia

Identifiers

PMID26884167
PMCPMC4780638
OpenAlexW2275744255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.